| This week's sponsor is Premier Research. | |  | Discovering the Great Potential of Immuno-Oncology Drugs
Immuno-modulating agents have been around a long time, but for limited uses. New immuno-oncology pathways promise big advances against a wider range of cancers. Register now for our May 23 webinar. Premier Research. It's what we do. Best. |
Featured Story | Thursday, May 4, 2017  Newly born European biotech Vivet Therapeutics has started life with €37.5 million ($41 million) and an executive team made up of Novartis, Sanofi and Gensight veterans, as the company looks to get to work on its gene therapies for a host of rare diseases.
|
|
|
| This week's sponsor is Sensors Expo & Conference 2017. | |  | |
Top Stories | Thursday, May 4, 2017 Novartis has bolstered its R&D portfolio for NASH, a progressive fatty liver disease tipped to become a $20 billion to $35 billion market in the coming years, with its second deal in a month. |
|
|
| Thursday, May 4, 2017 A phase 2b trial of Poxel’s Type 2 diabetes candidate imeglimin has met its primary endpoint. The data sent shares in Poxel soaring 40% and set the company up to push into a phase 3 trial before the end of the year. |
|
|
Monday, April 24, 2017 It’s a critical tradeoff for life. Our bodies use sugar and fat from the food we consume to produce energy in our cells’ mitochondria, the internal powerhouses that give us the energy we need for all our vital functions. | Thursday, May 4, 2017 Gritstone Oncology has appointed Raphaël Rousseau, M.D., Ph.D., as its CMO. Rousseau joins Gritstone from Genentech, becoming the latest biopharma veteran to join the ranks at the well-financed personalized cancer immunotherapy startup. |
|
|
| Wednesday, May 3, 2017 LabCorp is planning a rejig of its CRO business Covance, and the short-term plan includes letting go of a lab along with the employees stationed there. |
|
|
| Thursday, May 4, 2017 Asia-Pacific CRO George Clinical has topped up its cancer services and boosted its U.S. presence after acquiring Memphis, Tennessee-based Vector Oncology's CRO division. |
|
|
| Wednesday, May 3, 2017 LivaNova, which specializes in neuromodulation, cardiac surgery and rhythm management, will acquire Caisson Interventional, a Minnesota-based heart valve maker, for $72 million. |
|
|
| Thursday, May 4, 2017 Despite what you may have heard about drug pricing and expenses getting out of hand, net spending growth actually fell in the U.S. last year. After discounts, pharmaceutical spending increased 4.8% in 2016, down from the 8.9% growth recorded in 2015. |
|
|
| This week's sponsor is J.P. Morgan Private Bank. | |  | How Pre-Transaction Planning Can Maximize Your Wealth
You've worked hard to build a successful healthcare business. To reap the rewards of a sale, merger, recap or IPO, be sure you maximize the value of your equity interests with careful pre-transaction planning. Learn how J.P. Morgan Private Bank can help you protect your wealth. Read the article. |
| | | Regeneron's R&D costs were $507 million in the first quarter compared to $470 million a year ago, with the extra cash going on development work for fasinumab and REGN2810. Regeneron's financials Rare disease biotech Rhythm has started a phase 3 test for setmelanotide, its first-in-class melanocortin-4 receptor, for an an ultrarare genetic disorder associated with severe, early-onset obesity and unrelenting appetite. Release Former CDR Therapeutics and Xcyte Therapies executive Che-Leung Law, Ph.D., has become the new VP of translational medicine at T-cell biotech Harpoon. Statement | |
|
Resources Presented By: Covance The ICH GCP E6 guideline has been revised to address the complexities associated with today’s clinical trials, and this concise white paper will help you understand the recent guideline changes. Learn how use of risk-based monitoring can help you comply with the guidelines and achieve efficiency in clinical trial design, implementation and reporting. Sponsored By: Veeva To thrive in a fiercely competitive market, life sciences companies need to set themselves apart by designing and executing the best trial and successfully deliver drugs to market first. Learn how a modern EDC can help. Sponsored By Reprints Desk Puzzled by Scientific Literature Access? Here is your guide for navigating knowledge management’s twists and turns! If yours is a small- or medium-sized biopharma business, we can help you putting the pieces together. Learn the secrets of top knowledge management experts who will show you how to search, discover, acquire and manage knowledge in new ways. Presented By: Covance The recent evolution of immunotherapies and their potential applications have greatly impacted patients’ options for effective oncology treatments. These advances have been powered in part by the use of biomarkers, companion diagnostics (CDx) and complementary diagnostics. Read the white paper. Sponsored By: DocuSign DocuSign’s eSignature solutions modernize healthcare and life science organizations by eliminating paper and antiquated signature processes while meeting compliance requirements and reducing costs and errors. Sponsored By: DocuSign The patients who rely on your scientific leadership are expecting more. Sponsored By: DocuSign The U.S. Department of Justice has collected upwards of $17 billion in settlements from the healthcare industry since 2009, including more than $2 billion from a single life sciences company. |
|
